What it is
IGF-1 is a 70-amino-acid single-chain polypeptide hormone (MW 7,649 Da, CAS 67763-96-6, UniProt P05019) that mediates most of the growth-promoting effects of pituitary growth hormone. It shares roughly 50% sequence homology with proinsulin — positions 1–29 map to the insulin B chain, 42–62 to the A chain, with a unique C-domain connecting peptide and a D-domain octapeptide extension not present in insulin. Three intramolecular disulfide bridges (6–48, 18–61, 47–52) stabilize the tertiary structure required for IGF-1R binding. The FDA-approved human therapeutic is mecasermin — non-glycosylated recombinant human IGF-1 produced in E. coli, marketed as Increlex (Ipsen). The research-chemical variant most commonly seen in off-label contexts is IGF-1 LR3 (Long R3 IGF-1), a synthetic analog with an Arg3→Glu substitution and a 13-residue N-terminal extension that reduces IGFBP binding and extends plasma half-life; LR3 is not FDA-approved for any indication and has no human PK data in peer-reviewed literature.
In plain English
IGF-1 is a natural hormone your body makes (mostly in your liver) that does most of the actual growing and tissue-building work after growth hormone tells the liver to produce it. It's a chain of 70 amino acids. Its shape looks about half like insulin — that's why at high doses it can also lower blood sugar like insulin does. The FDA-approved drug form (called mecasermin, brand name Increlex) is a lab-made exact copy grown in bacteria. The research-chemical version most commonly sold through back channels is "IGF-1 LR3" — a tweaked version with one amino acid swapped and a 13-piece tail added on. Those changes make it last much longer in the blood. LR3 is not FDA-approved for anything, and no human studies have ever measured how the body handles it.
How it works
- 01
IGF-1R autophosphorylation and receptor engagement
IGF-1 binds the type-1 IGF receptor (IGF-1R), a heterotetrameric transmembrane tyrosine kinase with ~50% homology to the insulin receptor. Binding triggers autophosphorylation at Tyr1131/1135/1136 in the kinase domain and Tyr950 in the juxtamembrane region (reviewed in Hakuno & Takahashi 2018). At pharmacologic concentrations, IGF-1 cross-binds the insulin receptor with roughly 0.1× the affinity of insulin — the basis for the hypoglycemia risk in the Increlex label.
In plain English
It latches onto its receiver and turns it on
IGF-1 plugs into a receiver on the outside of cells called the IGF-1 receptor. When it locks in, the receiver activates itself and starts sending signals inside the cell. This receiver looks about half like the insulin receiver — close enough that at drug-level doses, IGF-1 can also partly act like insulin and drop blood sugar. That's why the FDA-approved version carries a warning about low blood sugar.
- 02
PI3K–Akt–mTOR: the anabolic arm
Activated IGF-1R phosphorylates IRS-1, which recruits PI3K, generating PIP3, recruiting PDK1, and phosphorylating Akt at Thr308 (full activation requires Ser473 phosphorylation by mTORC2). Akt phosphorylates GSK3β (relieving inhibition of protein synthesis), FOXO1/3/4 (suppressing transcription of the E3 ligases MuRF1 and atrogin-1/MAFbx that mediate ubiquitin-proteasome muscle proteolysis), and TSC2 (activating mTORC1 → p70S6K, 4E-BP1, cap-dependent translation). This is the molecular basis for the anti-atrophy signal documented by Rommel 2001 (Nat Cell Biol) and Sandri 2004 (Cell).
In plain English
It turns on the muscle-building pathway inside cells
Once the receiver is on, IGF-1 triggers a chain of signals inside the cell. The chain tells the cell to build more protein and stop breaking down muscle. It even shuts off the enzymes that tag muscle fibers for destruction. This is the molecular reason IGF-1 is a textbook muscle-growth signal in cell and animal studies.
- 03
Ras–MAPK–ERK: the proliferative arm
In parallel, phosphorylated IGF-1R engages SHC, which recruits Grb2/SOS, activates Ras GTPase, and drives the Raf → MEK → ERK cascade. ERK signaling predominantly governs proliferation and differentiation. The co-activation of PI3K–Akt (survival/growth) and Ras–MAPK (proliferation) is the mechanistic reason IGF-1R is a recognized driver in most solid tumors and the reason anti-IGF-1R monoclonal antibodies have been developed as oncology agents (e.g., figitumumab, ganitumab — both abandoned for efficacy, but the mechanistic concern stands).
In plain English
It also turns on the "make more cells" signal — which is the cancer concern
At the same time IGF-1 tells cells to build more protein, it also tells cells to divide and make copies of themselves. That second signal is why IGF-1's receiver is a known driver of most solid-tumor cancers. Drug companies have even built cancer drugs designed to BLOCK the IGF-1 receiver. Those drugs did not work well enough to get approved. But the underlying concern — that IGF-1 feeds tumors — is real.
- 04
Satellite-cell activation and muscle hypertrophy in animal models
Barton-Davis 1998 (PNAS) used viral-mediated local IGF-1 gene transfer to mouse hindlimb and showed significant muscle mass and strength gains; gamma-irradiation of satellite cells eliminated ~50% of the effect, implying the remainder came from direct effects on differentiated myofibers. Musarò 2001 (Nat Genet) and the mIGF-1 transgenic line reproduced the hypertrophy in mice without elevating circulating IGF-1. These are the foundational animal studies cited by off-label users — they demonstrate local mechanism but do not translate to a published human RCT of systemic IGF-1 for healthy-adult muscle mass.
In plain English
It grows mouse muscle — in specific experiments, not in normal human use
In 1998, researchers used a virus to deliver IGF-1 directly into one hind leg of a mouse. That leg grew noticeably bigger and stronger than the other. A 2001 follow-up did something similar with genetic engineering. Bodybuilders often cite these studies. What they leave out: the drug was placed directly in the mouse leg. That is not the same as injecting IGF-1 or LR3 into a healthy adult and expecting bigger muscles. No human trial has ever shown that works.
- 05
IGFBP regulation and why free IGF-1 is rare
In serum, 70–80% of IGF-1 circulates in a 150-kDa ternary complex with IGFBP-3 and the acid-labile subunit (ALS), extending half-life from ~5 minutes (free) to ~20 hours (bound). About 20% is in 50-kDa binary complexes with the other five IGFBPs. Less than 5% is free. Proteolytic cleavage of IGFBPs by PAPP-A and related proteases liberates IGF-1 locally. The mecasermin rinfabate formulation (IGF-1 + IGFBP-3 co-administered) was designed to exploit this — but was discontinued. IGF-1 LR3's clinical logic in research-chemical channels is that its reduced IGFBP binding raises free IGF-1 — which is precisely why its safety margin is narrower than native IGF-1.
In plain English
Most IGF-1 in your blood is locked up — LR3 is dangerous because it breaks that lock
In your blood, most IGF-1 (about 70–80%) is locked up in a big complex with a carrier protein. That is your body's safety system. Less than 5% is free and active at any moment. Tissues that need IGF-1 cut the lock locally, where it matters. The whole trick of IGF-1 LR3 is that it was designed NOT to bind those carrier proteins. So almost all of it stays active. That is exactly why its safety margin is much narrower than regular IGF-1 — without the body's lockup system, there is no brake.
- 06
What is NOT known about the mechanism in off-label use
Tissue-specific signaling bias of systemic IGF-1 in healthy adults is not characterized. Chronic-dosing feedback (mTORC1 → S6K → IRS-1 degradation, generating insulin resistance; Copps & White 2012) is documented but its magnitude and reversibility at off-label doses are not published. The downstream proliferative consequence across tissues — particularly on prostate epithelium, colonic mucosa, and breast tissue, the three sites with the strongest Renehan 2004 meta-analysis signal — is the central safety question that off-label dosing regimens have not answered.
In plain English
What we still don't know
We do not really know which tissues get more signal and which get less when an adult injects IGF-1. Chronic dosing can create insulin resistance through a feedback loop. How bad it gets, and whether it reverses after stopping, has not been published at off-label doses. The biggest unanswered safety question: what happens in the tissues most linked to IGF-1-related cancer risk — prostate, colon, and breast — when someone takes IGF-1 for muscle for years?